Chief Legal Officer and Secretary · Kura Oncology, Inc. (KURA)

James Basta

FY2019 is the first fiscal year CompBrief holds for James Basta as a named executive officer of Kura Oncology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,933,832

Salary $63,749Stock awards $0Bonus $100,000

6th of 6 named executive officers at Kura Oncology by FY2019 total.

6 named officers on file for Kura Oncology, FY2019

James Basta’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • KURA’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kura Oncology’s whole pay program stands against its peers

  • Kura Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KURA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2020 (DEF 14A).

Free

Get James Basta’s full pay file as a PDF — free

More than this page: up to 10 years of James’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

James Basta compensation by year

Kura Oncology Summary Compensation Table · the one fiscal year held
In US dollars, as Kura Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$63,749
Bonus$100,000
Stock awards$0
Option awards$1,764,893
Non-equity incentive$0
Pension and deferred compensation$0
All other$5,190
Total$1,933,832

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kura Oncology, Inc. DEF 14A filed April 28, 2020, accession 0001564590-20-019201, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kura Oncology, Inc. filed document, accession 0001564590-20-019201. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option175,000—$15.36

Per the Outstanding Equity Awards at Fiscal Year-End table in Kura Oncology, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Kura Oncology’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Kathleen FordChief Operating Officer$3,485,030
Troy WilsonPresident and Chief Executive Officer$3,236,217
John FarnamFormer Chief Operating Officer$2,163,376
Marc GrassoFormer Chief Financial Officer and Chief Business Officer$2,112,282
Antonio GualbertoFormer Head of Development and Chief Medical Officer$2,050,193
James Basta · this pageChief Legal Officer and Secretary$1,933,832

The full Kura Oncology compensation record

free company brief

This page is one person within Kura Oncology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kura Oncology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kura Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

James Basta's compensation dossier · One-time report. No refunds.